Oxidative stress in Parkinson's disease
暂无分享,去创建一个
[1] A. Schapira,et al. Evidence for mitochondrial dysfunction in Parkinson's disease—a critical appraisal , 2004, Movement disorders : official journal of the Movement Disorder Society.
[2] H. Hefter,et al. Is levodopa toxic? , 2004, Journal of Neurology.
[3] B. Halliwell,et al. Proteasomal dysfunction induced by 4‐hydroxy‐2,3‐trans‐nonenal, an end‐product of lipid peroxidation: a mechanism contributing to neurodegeneration? , 2002, Journal of neurochemistry.
[4] N. Hattori,et al. Effect of Wild-type or Mutant Parkin on Oxidative Damage, Nitric Oxide, Antioxidant Defenses, and the Proteasome* , 2002, The Journal of Biological Chemistry.
[5] B. Halliwell,et al. The cytotoxicity of dopamine may be an artefact of cell culture , 2002, Journal of neurochemistry.
[6] B. Halliwell,et al. 5‐S‐Cysteinyl‐conjugates of catecholamines induce cell damage, extensive DNA base modification and increases in caspase‐3 activity in neurons , 2002, Journal of neurochemistry.
[7] P. Mander,et al. Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration , 2002, Neuroscience.
[8] S. Shin,et al. Formation and Removal of α-Synuclein Aggregates in Cells Exposed to Mitochondrial Inhibitors* , 2002, The Journal of Biological Chemistry.
[9] R. Swanson,et al. Poly(ADP-ribose) glycohydrolase mediates oxidative and excitotoxic neuronal death , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[10] Barry Halliwell,et al. Failure of the ubiquitin–proteasome system in Parkinson's disease , 2001, Nature Reviews Neuroscience.
[11] Moonhee Lee,et al. Effect of proteasome inhibition on cellular oxidative damage, antioxidant defences and nitric oxide production , 2001, Journal of neurochemistry.
[12] R. Swanson,et al. Astrocytes protect neurons from nitric oxide toxicity by a glutathione‐dependent mechanism , 2001, Journal of neurochemistry.
[13] MoonHee Lee,et al. Effect of the overexpression of wild‐type or mutant α‐synuclein on cell susceptibility to insult , 2001 .
[14] K. McNaught,et al. Proteasomal function is impaired in substantia nigra in Parkinson's disease , 2001, Neuroscience Letters.
[15] K. O’Malley,et al. The Parkinsonism-inducing Drug 1-Methyl-4-phenylpyridinium Triggers Intracellular Dopamine Oxidation , 2000, The Journal of Biological Chemistry.
[16] J. Trojanowski,et al. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. , 2000, Science.
[17] N. Tatton. Increased Caspase 3 and Bax Immunoreactivity Accompany Nuclear GAPDH Translocation and Neuronal Apoptosis in Parkinson's Disease , 2000, Experimental Neurology.
[18] J. Trojanowski,et al. Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies. , 2000, The American journal of pathology.
[19] K. McNaught,et al. Extracellular accumulation of nitric oxide, hydrogen peroxide, and glutamate in astrocytic cultures following glutathione depletion, complex I inhibition, and/or lipopolysaccharide-induced activation. , 2000, Biochemical pharmacology.
[20] C. Fall,et al. Disrupted mitochondrial electron transport function increases expression of anti‐apoptotic Bcl‐2 and Bcl‐XL proteins in SH‐SY5Y neuroblastoma and in Parkinson disease cybrid cells through oxidative stress , 2000, Journal of neuroscience research.
[21] E. Daikhin,et al. Proteolytic degradation of tyrosine nitrated proteins. , 2000, Archives of biochemistry and biophysics.
[22] R J Miller,et al. The selective toxicity of 1-methyl-4-phenylpyridinium to dopaminergic neurons: the role of mitochondrial complex I and reactive oxygen species revisited. , 2000, Molecular pharmacology.
[23] K. McNaught,et al. Dysfunction of rat forebrain astrocytes in culture alters cytokine and neurotrophic factor release , 2000, Neuroscience Letters.
[24] L. Shulman. Levodopa toxicity in Parkinson disease: reality or myth? Reality--practice patterns should change. , 2000, Archives of neurology.
[25] T. Miyata,et al. 4-hydroxynonenal induces a cellular redox status-related activation of the caspase cascade for apoptotic cell death. , 2000, Journal of cell science.
[26] M. Mattson,et al. The Lipid Peroxidation Product 4‐Hydroxy‐2,3‐Nonenal Increases AP‐1‐Binding Activity Through Caspase Activation in Neurons , 2000, Journal of neurochemistry.
[27] S. Pennathur,et al. Mass Spectrometric Quantification of 3-Nitrotyrosine, ortho-Tyrosine, and o,o′-Dityrosine in Brain Tissue of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated Mice, a Model of Oxidative Stress in Parkinson's Disease* , 1999, The Journal of Biological Chemistry.
[28] K. McNaught,et al. Altered Glial Function Causes Neuronal Death and Increases Neuronal Susceptibility to 1‐Methyl‐4‐Phenylpyridinium‐ and 6‐Hydroxydopamine‐Induced Toxicity in Astrocytic/Ventral Mesencephalic Co‐Cultures , 1999, Journal of neurochemistry.
[29] Ted M. Dawson,et al. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease , 1999, Nature Medicine.
[30] S. Shimohama,et al. Depletion of Intracellular Glutathione Increases Susceptibility to Nitric Oxide in Mesencephalic Dopaminergic Neurons , 1999 .
[31] Keiji Tanaka,et al. 4-Hydroxy-2-nonenal-mediated Impairment of Intracellular Proteolysis during Oxidative Stress , 1999, The Journal of Biological Chemistry.
[32] D. Guastella,et al. Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[33] T. Montine,et al. Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. , 1999, The American journal of pathology.
[34] Paola Piccini,et al. The role of inheritance in sporadic Parkinson's disease: Evidence from a longitudinal study of dopaminergic function in twins , 1999, Annals of neurology.
[35] T. Montine,et al. 4‐Hydroxy‐2(E)‐Nonenal Inhibits CNS Mitochondrial Respiration at Multiple Sites , 1999, Journal of neurochemistry.
[36] M. Beal,et al. Increased nitrotyrosine immunoreactivity in substantia nigra neurons in MPTP treated baboons is blocked by inhibition of neuronal nitric oxide synthase , 1999, Brain Research.
[37] J. P. Henderson,et al. 8-Nitro-2'-deoxyguanosine, a specific marker of oxidation by reactive nitrogen species, is generated by the myeloperoxidase-hydrogen peroxide-nitrite system of activated human phagocytes. , 1999, Biochemistry.
[38] T. Reinheckel,et al. Comparative resistance of the 20S and 26S proteasome to oxidative stress. , 1998, The Biochemical journal.
[39] A. Lees,et al. Conjugates of Catecholamines with Cysteine and GSH in Parkinson's Disease: Possible Mechanisms of Formation Involving Reactive Oxygen Species , 1998, Journal of neurochemistry.
[40] A. Kingsbury,et al. DNA fragmentation in human substantia nigra: Apoptosis or perimortem effect? , 1998, Movement disorders : official journal of the Movement Disorder Society.
[41] H. Li,et al. Brain Mitochondria Catalyze the Oxidation of 7‐(2‐Aminoethyl)‐3,4‐Dihydro‐5‐Hydroxy‐2H‐1,4‐Benzothiazine‐3‐Carboxylic Acid (DHBT‐1) to Intermediates that Irreversibly Inhibit Complex I and Scavenge Glutathione: Potential Relevance to the Pathogenesis of Parkinson's Disease , 1998, Journal of neurochemistry.
[42] P. Damier,et al. Glial cells and inflammation in parkinson's disease: A role in neurodegeneration? , 1998, Annals of neurology.
[43] J. Obeso,et al. Subthalamic nucleus‐mediated excitotoxicity in parkinson's disease: A target for neuroprotection , 1998, Annals of neurology.
[44] D. Perl,et al. A fluorescent double‐labeling method to detect and confirm apoptotic nuclei in parkinson's disease , 1998, Annals of neurology.
[45] M. Beal,et al. Excitotoxicity and nitric oxide in parkinson's disease pathogenesis , 1998, Annals of neurology.
[46] P. Jenner,et al. Understanding cell death in parkinson's disease , 1998, Annals of neurology.
[47] S. Shimohama,et al. Dopamine D2‐type agonists protect mesencephalic neurons from glutamate neurotoxicity: Mechanisms of neuroprotective treatment against oxidative stress , 1998, Annals of neurology.
[48] E. Clementi,et al. Persistent inhibition of cell respiration by nitric oxide: crucial role of S-nitrosylation of mitochondrial complex I and protective action of glutathione. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[49] J. Cano,et al. Lipopolysaccharide Intranigral Injection Induces Inflammatory Reaction and Damage in Nigrostriatal Dopaminergic System , 1998, Journal of neurochemistry.
[50] D. Perl,et al. Protein Nitration in Parkinson's Disease , 1998, Journal of neuropathology and experimental neurology.
[51] J S Rakshi,et al. Measuring the rate of progression and estimating the preclinical period of Parkinson’s disease with [18F]dopa PET , 1998, Journal of neurology, neurosurgery, and psychiatry.
[52] S. Daniel,et al. Glial pathology but absence of apoptotic nigral neurons in long‐standing Parkinson's disease , 1998, Movement disorders : official journal of the Movement Disorder Society.
[53] E. Floor,et al. Increased Protein Oxidation in Human Substantia Nigra Pars Compacta in Comparison with Basal Ganglia and Prefrontal Cortex Measured with an Improved Dinitrophenylhydrazine Assay , 1998, Journal of neurochemistry.
[54] P. Leigh,et al. Increased mitochondrial superoxide dismutase activity in Parkinson's disease but not amyotrophic lateral sclerosis motor cortex , 1997, Neuroscience Letters.
[55] C. Fall,et al. Elevated reactive oxygen species and antioxidant enzyme activities in animal and cellular models of Parkinson's disease. , 1997, Biochimica et biophysica acta.
[56] J. Blumberg,et al. Regulation of Ubiquitin-conjugating Enzymes by Glutathione Following Oxidative Stress* , 1997, The Journal of Biological Chemistry.
[57] S. Fahn. Levodopa-Induced Neurotoxicity , 1997 .
[58] V. Davila,et al. Neurotrophic Effects of l‐DOPA in Postnatal Midbrain Dopamine Neuron/Cortical Astrocyte Cocultures , 1997, Journal of neurochemistry.
[59] C D Marsden,et al. Oxidative DNA Damage in the Parkinsonian Brain: An Apparent Selective Increase in 8‐Hydroxyguanine Levels in Substantia Nigra , 1997, Journal of neurochemistry.
[60] K. Marder,et al. Altered systemic iron metabolism in Parkinson's disease , 1997, Neurology.
[61] A. Lees,et al. A Generalised Increase in Protein Carbonyls in the Brain in Parkinson's but Not Incidental Lewy Body Disease , 1997, Journal of neurochemistry.
[62] J. Bennett,et al. Mitochondrial toxins in models of neurodegenerative diseases. I: in vivo brain hydroxyl radical production during sytemic MPTP treatment or following microdialysis infusion of methylpyridinium or azide ions , 1997, Brain Research.
[63] J. Bennett,et al. Mitochondrial toxins in models of neurodegenerative diseases. II: elevated zif268 transcription and independent temporal regulation of striatal D1 and D2 receptor mRNAs and D1 and D2 receptor-binding sites in C57BL/6 mice during MPTP treatment , 1997, Brain Research.
[64] P. Jenner,et al. Nitric oxide synthase inhibition and MPTP‐induced toxicity in the common marmoset , 1997, Synapse.
[65] J M Land,et al. Nitric Oxide‐Mediated Mitochondrial Damage in the Brain: Mechanisms and Implications for Neurodegenerative Diseases , 1997, Journal of neurochemistry.
[66] N. Hattori,et al. An immunohistochemical study on manganese superoxide dismutase in Parkinson's disease , 1997, Journal of the Neurological Sciences.
[67] K. Hoyt,et al. Mechanisms of Dopamine-Induced Cell Death in Cultured Rat Forebrain Neurons: Interactions with and Differences from Glutamate-Induced Cell Death , 1997, Experimental Neurology.
[68] M. Graeber,et al. On the question of apoptosis in the parkinsonian substantia nigra , 1997, Acta Neuropathologica.
[69] A. Barzilai,et al. Levodopa induces apoptosis in cultured neuronal cells—A possible accelerator of nigrostriatal degeneration in Parkinson's disease? , 1997, Movement disorders : official journal of the Movement Disorder Society.
[70] Y. Goshima,et al. Differential neurotoxicity induced by l-DOPA and dopamine in cultured striatal neurons , 1996, Brain Research.
[71] R. Wyatt,et al. Dopamine induces apoptotic cell death of a catecholaminergic cell line derived from the central nervous system. , 1996, Molecular pharmacology.
[72] M. Beal,et al. Inhibition of neuronal nitric oxide synthase prevents MPTP–induced parkinsonism in baboons , 1996, Nature Medicine.
[73] F. Colpaert,et al. Poly(ADP-ribose) polymerase inhibitors protect against MPTP-induced depletions of striatal dopamine and cortical noradrenaline in C57B1/6 mice , 1996, Brain Research.
[74] G. Dryhurst,et al. Further insights into the influence of L-cysteine on the oxidation chemistry of dopamine: reaction pathways of potential relevance to Parkinson's disease. , 1996, Chemical research in toxicology.
[75] T. Dawson,et al. Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[76] Y. Agid,et al. Nitric oxide synthase and neuronal vulnerability in parkinson's disease , 1996, Neuroscience.
[77] Y. Mizuno,et al. Histochemical detection of apoptosis in Parkinson's disease , 1996, Journal of the Neurological Sciences.
[78] J. Bolaños,et al. Depletion of brain glutathione results in a decrease of glutathione reductase activity; an enzyme susceptible to oxidative damage , 1996, Brain Research.
[79] N. Hattori,et al. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[80] M. O’connor,et al. DNA strand breakage, activation of poly (ADP-ribose) synthetase, and cellular energy depletion are involved in the cytotoxicity of macrophages and smooth muscle cells exposed to peroxynitrite. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[81] S. K. Han,et al. l‐DOPA Up‐Regulates Glutathione and Protects Mesencephalic Cultures Against Oxidative Stress , 1996, Journal of neurochemistry.
[82] M. Mena,et al. Glia conditioned medium protects fetal rat midbrain neurones in culture from L‐DOPA toxicity , 1996, Neuroreport.
[83] J. Connor,et al. A Quantitative Analysis of Isoferritins in Select Regions of Aged, Parkinsonian, and Alzheimer's Diseased Brains , 1995, Journal of neurochemistry.
[84] B. Halliwell,et al. Superoxide‐dependent depletion of reduced glutathione by L‐DOPA and dopamine. Relevance to Parkinson's disease , 1995, Neuroreport.
[85] N. Hattori,et al. Role of mitochondria in the etiology and pathogenesis of Parkinson's disease. , 1995, Biochimica et biophysica acta.
[86] C. Marsden,et al. L‐Dihydroxyphenylalanine and complex I deficiency in Parkinson's disease brain , 1995, Movement disorders : official journal of the Movement Disorder Society.
[87] M. Youdim,et al. Inhibition of mitochondrial complexes I and IV by 6-hydroxydopamine. , 1995, European journal of pharmacology.
[88] J. Schulz,et al. Inhibition of Neuronal Nitric Oxide Synthase by 7‐Nitroindazole Protects Against MPTP‐Induced Neurotoxicity in Mice , 1995, Journal of neurochemistry.
[89] Y. Glinka,et al. Dopamine Neurotoxicity: Inhibition of Mitochondrial Respiration , 1995, Journal of neurochemistry.
[90] C. Morris,et al. Iron histochemistry of the substantia nigra in Parkinson's disease. , 1994, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.
[91] C. Marsden,et al. Complex I, Iron, and ferritin in Parkinson's disease substantia nigra , 1994, Annals of neurology.
[92] P. Jenner. Oxidative damage in neurodegenerative disease , 1994, The Lancet.
[93] S. Daniel,et al. Glutathione‐related enzymes in brain in Parkinson's disease , 1994, Annals of neurology.
[94] C. Marsden,et al. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia , 1994, Annals of neurology.
[95] F. Jiménez-Jiménez,et al. Peripheral iron metabolism in patients with Parkinson's disease , 1994, Journal of the Neurological Sciences.
[96] Kanefusa Kato,et al. Cerebrospinal fluid levels of superoxide dismutases in neurological diseases detected by sensitive enzyme immunoassays , 1994, Journal of the Neurological Sciences.
[97] Mitsutoshi Yamamoto,et al. Differential effects of chronic l-DOPA treatment on lipid peroxidation in the mouse brain with or without pretreatment with 6-hydroxydopamine , 1994, Neuroscience Letters.
[98] C. Marsden,et al. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease , 1994, Annals of neurology.
[99] J. Cooper,et al. Iron induced oxidative stress and mitochondrial dysfunction: relevance to Parkinson's disease , 1993, Brain Research.
[100] J. Coyle,et al. Oxidative stress, glutamate, and neurodegenerative disorders. , 1993, Science.
[101] C. Mytilineou,et al. Toxic and Protective Effects of l‐DOPA on Mesencephalic Cell Cultures , 1993, Journal of neurochemistry.
[102] P. Jenner,et al. Altered mitochondrial function, iron metabolism and glutathione levels in Parkinson's disease , 1993, Acta neurologica Scandinavica. Supplementum.
[103] E. Hirsch,et al. Glutathione peroxidase, glial cells and Parkinson's disease , 1993, Neuroscience.
[104] C. Marsden,et al. New insights into the cause of Parkinson's disease , 1992, Neurology.
[105] S. Fahn,et al. The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it , 1992, Annals of neurology.
[106] Barry Halliwell,et al. Reactive Oxygen Species and the Central Nervous System , 1992, Journal of neurochemistry.
[107] C. W. Olanow,et al. Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study , 1992, Brain Research.
[108] K. Jellinger,et al. Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease , 1992, Neuroscience Letters.
[109] D. D. Di Monte,et al. Mitochondrial poisons cause depletion of reduced glutathione in isolated hepatocytes. , 1992, Archives of biochemistry and biophysics.
[110] C. Epstein,et al. Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[111] S. Markey,et al. Search for neurotoxins structurally related to 1-methyl-4-phenylpyridine (MPP+) in the pathogenesis of Parkinson's disease , 1992, Brain Research.
[112] J. Connor,et al. A histochemical study of iron, transferrin, and ferritin in Alzheimer's diseased brains , 1992, Journal of neuroscience research.
[113] P. Jenner. Oxidative stress as a cause of Parkinson's disease , 1991, Acta neurologica Scandinavica. Supplementum.
[114] C D Marsden,et al. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. , 1991, Brain : a journal of neurology.
[115] P. Johannsen,et al. Glutathione peroxidase in early and advanced Parkinson's disease. , 1991, Journal of neurology, neurosurgery, and psychiatry.
[116] S. Hirai,et al. Dopa and dopamine cause cultured neuronal death in the presence of iron , 1991, Journal of the Neurological Sciences.
[117] Y. Agid,et al. Iron and Aluminum Increase in the Substantia Nigra of Patients with Parkinson's Disease: An X‐Ray Microanalysis , 1991, Journal of neurochemistry.
[118] D. Reif,et al. Nitric oxide mediates iron release from ferritin. , 1990, Archives of biochemistry and biophysics.
[119] K. Jellinger,et al. Normal Mitochondrial Genome in Brain from Patients with Parkinson's Disease and Complex I Defect , 1990, Journal of neurochemistry.
[120] Mazen Al-Hakim,et al. Magnetic Resonance Imaging in Multiple Sclerosis , 1990, Neurology.
[121] C. Marsden,et al. Decreased Ferritin Levels in Brain in Parkinson's Disease , 1990, Journal of neurochemistry.
[122] B. Freeman,et al. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[123] P. Riederer,et al. Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration? , 1989, Acta neurologica Scandinavica. Supplementum.
[124] Y. Kagawa,et al. Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. , 1989, Biochemical and biophysical research communications.
[125] C. Marsden,et al. A Selective Increase in Particulate Superoxide Dismutase Activity in Parkinsonian Substantia Nigra , 1989, Journal of neurochemistry.
[126] A. H. V. Schapira,et al. MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE , 1989, The Lancet.
[127] C. Marsden,et al. Increased Nigral Iron Content and Alterations in Other Metal Ions Occurring in Brain in Parkinson's Disease , 1989, Journal of neurochemistry.
[128] E. Mukai,et al. [Magnetic resonance imaging of parkinsonism]. , 1989, Rinsho shinkeigaku = Clinical neurology.
[129] G. Ebers,et al. Abnormalities in Iron Metabolism in Multiple Sclerosis , 1989, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[130] Peter Riederer,et al. Transition Metals, Ferritin, Glutathione, and Ascorbic Acid in Parkinsonian Brains , 1989, Journal of neurochemistry.
[131] C. Marsden,et al. Basal Lipid Peroxidation in Substantia Nigra Is Increased in Parkinson's Disease , 1989, Journal of neurochemistry.
[132] G. Cohen,et al. Exposure of striatal [corrected] synaptosomes to L-dopa increases levels of oxidized glutathione. , 1988, The Journal of pharmacology and experimental therapeutics.
[133] R. Marttila,et al. Oxygen toxicity protecting enzymes in Parkinson's disease Increase of superoxide dismutase-like activity in the substantia nigra and basal nucleus , 1988, Journal of the Neurological Sciences.
[134] S. Kish,et al. Glutathione peroxidase activity in Parkinson's disease brain , 1985, Neuroscience Letters.
[135] R. Clavier,et al. Nigrostriatal Dopaminergic Neurons Remain Undamaged in Rats Given High Doses of l‐DOPA and Carbidopa Chronically , 1984, Journal of neurochemistry.
[136] D. Godin,et al. Parkinson's disease: A disorder due to nigral glutathione deficiency? , 1982, Neuroscience Letters.
[137] R. Wurtman,et al. Long‐term administration of L‐DOPA does not damage dopaminergic neurons in the mouse , 1981, Neurology.
[138] D. Graham. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. , 1978, Molecular pharmacology.
[139] M. V. Van Woert,et al. Brain peroxidase and catalase in Parkinson disease. , 1975, Archives of neurology.
[140] G. Cohen,et al. The generation of hydrogen peroxide, superoxide radical, and hydroxyl radical by 6-hydroxydopamine, dialuric acid, and related cytotoxic agents. , 1974, The Journal of biological chemistry.
[141] R. Adams,et al. 6-Hydroxydopamine, a new oxidation mechanism. , 1972, European journal of pharmacology.
[142] G. Reynolds,et al. Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain , 2005, Journal of Neural Transmission.
[143] C. Marsden,et al. Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease , 2005, Journal of Neural Transmission.
[144] P. Mcgeer,et al. Expression of the histocompatibility glycoprotein HLA-DR in neurological disease , 2004, Acta Neuropathologica.
[145] B. Halliwell,et al. Chronic high dose L-DOPA alone or in combination with the COMT inhibitor entacapone does not increase oxidative damage or impair the function of the nigro-striatal pathway in normal cynomologus monkeys , 2002, Journal of Neural Transmission.
[146] B. Halliwell,et al. Effect of the overexpression of wild-type or mutant alpha-synuclein on cell susceptibility to insult. , 2001, Journal of neurochemistry.
[147] H. Li,et al. Oxidative metabolites of 5-S-cysteinyldopamine inhibit the α-ketoglutarate dehydrogenase complex: possible relevance to the pathogenesis of Parkinson's disease , 2000, Journal of Neural Transmission.
[148] D. Riley. Is levodopa toxic to human substantia nigra? , 1998, Movement disorders : official journal of the Movement Disorder Society.
[149] Y. Agid,et al. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. , 1997, Histology and histopathology.
[150] J. Bolaños,et al. Nitric oxide-mediated mitochondrial damage: a potential neuroprotective role for glutathione. , 1996, Free radical biology & medicine.
[151] J. Greene,et al. Bioenergetics and excitotoxicity: The weak excitotoxic hypothesis , 1996 .
[152] N. Ogawa. Levodopa and dopamine agonists in the treatment of Parkinson's disease: advantages and disadvantages. , 1994, European neurology.
[153] C. Marsden,et al. Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: An HPLC and ESR study , 1994, Movement disorders : official journal of the Movement Disorder Society.
[154] P. Scheltens,et al. Cerebrospinal fluid ferritin levels of patients with Parkinson's disease, Alzheimer's disease, and multiple system atrophy , 1994, Journal of neural transmission. Parkinson's disease and dementia section.
[155] T. Yoshikawa. Free radicals and their scavengers in Parkinson's disease. , 1993, European neurology.
[156] K. Mizukawa,et al. Degeneration of dopaminergic neurons and free radicals. Possible participation of levodopa. , 1993, Advances in neurology.
[157] 栄治 長谷川. 1-methyl-4-phenylpyridinium (MPP[+]) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles , 1993 .
[158] C. Marsden,et al. Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental lewy body disease , 1992, Annals of neurology.
[159] T. Chase,et al. L‐dopa does not affect electron transfer chain enzymes and respiration of rat muscle mitochondria , 1991, Movement disorders : official journal of the Movement Disorder Society.
[160] K. Jellinger,et al. Brain iron and ferritin in Parkinson's and Alzheimer's diseases , 1990, Journal of neural transmission. Parkinson's disease and dementia section.
[161] N. Quinn,et al. Preservation of the substanitia nigra and locus coeruleus in a patient receiving levodopa (2 kg) plus decarboxylase inhibitor over a four‐year period , 1986, Movement disorders : official journal of the Movement Disorder Society.
[162] D. Tse,et al. Potential oxidative pathways of brain catecholamines. , 1976, Journal of medicinal chemistry.
[163] K. Earle. Studies on Parkinson's disease including x-ray fluorescent spectroscopy of formalin fixed brain tissue. , 1968, Journal of neuropathology and experimental neurology.
[164] W. Gibb,et al. Occasional Review , 2022 .